Long-term efficacy and safety of rituximab in the treatment of neuromyelitis Optica Spectrum disorder
Background Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, autoimmune, inflammatory astrocytopathy. Rituximab for B-cell suppression is a common treatment for NMOSD; however, large-scale randomised controlled trials are lacking. Objective Evaluate long-term efficacy and safety of ritu...
שמור ב:
| Principais autores: | , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
SAGE Publishing
2024-04-01
|
| סדרה: | Multiple Sclerosis Journal - Experimental, Translational and Clinical |
| גישה מקוונת: | https://doi.org/10.1177/20552173241257876 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|